UNAIDS - 3 November 2009

On 29 October, the UNAIDS Liaison Office to the European Union organized a roundtable to discuss UNITAID's initiative to create a voluntary Patent Pool for AIDS medicines. The meeting brought together representatives of the European Commission, Medecins Sans Frontieres, European AIDS Treatment Groups and representatives from the pharmaceutical industry.

UNITAID, an international drug purchase facility, has taken the first steps to create a voluntary patent pool for AIDS medicines for developing countries for the public good.

Intellectual Property Rights

A patent is a form of ownership, intellectual property, which covers creations of the mind including inventions and pharmaceuticals. It acts as an incentive for companies to invest in research and development, knowing that with a monopoly in the market place, they stand a good chance of recouping their investment and making a profit.

Patents are regulated through the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property rights (TRIPS) together with the Doha Declaration on TRIPS and Public health and other World Trade Organization key decisions.

HIV-related patents remain a controversial topic between AIDS activists and the major pharmaceutical companies; while drug prices have dropped dramatically, newer products - such as second line treatment - are still very expensive.

Patent Pools - the solution?

UNITAID argues that a patent pool could be one of the solutions to expand access to more appropriate and lower priced medicines in low- and middle-income countries.

A patent pool is when patent rights held by different owners such as universities, pharmaceutical companies or government institutions, are brought together and made available on a non-exclusive basis.

Through this mechanism pharmaceutical producers could access a "one-stop-shop" for patents. In return producers would pay royalty to the patent holder.

Such a pool could make it easier to produce new medicines that combine several pharmaceutical compounds patented by different companies into a single pill. These medicines, known as "fixed-dose combinations" are easier than multiple tablets for children and adults to take, promoting HIV treatment compliance and boosting treatment outcomes.

The patent pool could also make newer medicines more affordable and accessible in developing countries, through opening up for completion between different producers as well as producers not having to wait to the end of the paten term (usually 20years).

The need for affordable HIV treatment will become more urgent as increasing numbers of people living with HIV fail their first-line therapy and need second-line treatments.

Moving the Patent Pool agenda forward

The purpose of the UNAIDS-hosted meeting was to present the creation of the patent pool to stakeholders. Discussions were broad-ranging and a constructive dialogue took place.

Ellen 't Hoen who is Senior Intellectual Property and Medicines Patent Pool advisor with UNITAID gave an overview on the ongoing discussions between the pharmaceutical industries and UNITAID which include terms of license agreements.

Questions on how pharmaceuticals could effectively work with the patent pool were raised by Brendan Barnes, Director at the European Federation of Pharmaceutical Industries, indicating his members' willingness to engage if adequate data on the functions of the patent pool is made available.

Wim Vandevelde, Chair of the European Community Advisory Board of the European AIDS Treatment Groups (EATG) welcomed the current scope of the patent pool including Middle Income countries and urged UNTAID to stand firm on this point in the negotiations with the patent holders. "We appreciate the cautious welcome from the pharmaceutical industry but we all know that the devil will be in the detail," said Mr Vandevelde.

The meeting ended with a bold call from the EATG and Medecins Sans Frontieres (MSF) who challenged pharmaceutical partners "to jump into the patent pool and get yourselves wet, in order to prevent millions of avoidable deaths."

"Newer, better antiretrovirals are already used by patients in the US and Europe, but aren't available to people in developing countries... We need these newer drugs, with fewer side effects, to gradually replace older treatments," said Michelle Childs, Director of Policy & Advocacy, MSF Campaign for Access to Essential Medicines.

"By making these drugs more affordable, a patent pool will ensure the delivery of these newer drugs for people in the developing world."

The UNAIDS Liaison Office to the European Union provides advice and assistance in the conduct of relations between UNAIDS and the European Institutions, as well as other international bodies and civil society organizations located in Brussels, and ensures that the global AIDS epidemic is effectively addressed by them as a priority. The Office also aims to increase senior policy dialogue between UNAIDS and the European Union institutions.

Resources:

Related information:

Intellectual property - http://www.unaids.org/en/PolicyAndPractice/HIVTreatment/Intellect Property/default.asp

Human rights and HIV - http://www.unaids.org/en/PolicyAndPractice/HumanRights/default.as p

External links:

UNITAID - http://www.unitaid.eu/

Medecins Sans Frontieres - http://www.msf.org/

European AIDS Treatment Groups - http://www.eatg.org/

European Commission - http://ec.europa.eu/index_en.htm

WTO - http://www.wto.org/

Publications:

International Guidelines on HIV/AIDS and Human Rights (pdf, 932 Kb) - http://data.unaids.org/Publications/IRC-pub07/jc1252-internguidel ines_en.pdf

The UNAIDS Guide to the United Nations Human Rights Machinery (3.53 Mb) - http://data.unaids.org/Publications/IRC-pub01/JC128-HRMachinery_e n.pdf

091103
UN091102

Copyright © 2009 - Joint United Nations Programme on HIV/AIDS (UNAIDS). All rights reserved. UNAIDS articles, which are not formal publications of UNAIDS, may be freely reviewed, quoted, reproduced or translated, in part or in full, provided the source is acknowledged. The documents may not be sold or used in conjunction with commercial purposes without prior written approval from UNAIDS (contact: UNAIDS Information Centre).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .